The aim of this study was to investigate the incidence of influenza-related encephalitis in Sweden during 11.5 years. Studies from Japan report an increased incidence of influenza-related encephalitis/encephalopathy. Few other studies are available. We conducted a retrospective register-based study on the Swedish National Inpatient Register, which covers all Swedish hospitals. In 1987–1998, a total number of 14,250 hospitalized individuals had an influenza diagnosis (population incidence: 137 per million personyears). In-hospital mortality was 4.1%. Using three different approaches, only 21 cases of influenza-related encephalitis were found, corresponding to a rate of 1.5 per 1,000 hospitalized persons with an influenza diagnosis (population incidence 0.21 per million person-years). We conclude that encephalitis following influenza occurs rarely, or is an infrequently recognized, diagnosed or reported complication. The cases we studied in detail have all recovered without sequels.

Keywords:
Influenza, Encephalitis, Sweden
1.
Szucs T: The socio-economic burden of influenza. J Antimicrob Chemother 1999;44 (suppl B):11–15.
2.
Kuszewski K, Brydak L: The epidemiology and history of influenza. Biomed Pharmacother 2000;54:188–195.
3.
Louria D, Blumenfeld H, Ellis J, Kilbourne E, Rogers D: Studies on influenza in the pandemic of 1957–1958. II. pulmonary complications of influenza. J Clin Invest 1959;38:213–265.
4.
Middleton P, Alexander R, Szymanski M: Severe myositis during recovery from influenza. Lancet 1970;ii:533–535.
5.
Minow R, Gorbach S, Johnson BJ, Dornfeld L: Myoglobinuria associated with influenza A infection. Ann Intern Med 1974;80:359–361.
6.
Dietzman D, Schaller J, Ray C, Reed ME: Acute myositis associated with influenza B infection. Pediatrics 1976;57:255–258.
7.
Nicholson K: Clinical features of influenza. Semin Respir Infect 1992;7:26–37.
8.
Hayase Y, Tobita K: Influenza virus and neurological diseases. Psychiatry Clin Neurosci 1997;51:181–184.
9.
Ravenholt RT, Foege WH: 1918 influenza, encephalitis lethargica, parkinsonism. Lancet 1982;ii:860–864.
10.
Maurizi CP: Why was the 1918 influenza pandemic so lethal? The possible role of a neurovirulent neuraminidase. Med Hypotheses 1985;16:1–5.
11.
Maurizi CP: Influenza caused epidemic encephalitis (encephalitis lethargica): the circumstantial evidence and a challenge to the naysayers. Med Hypotheses 1989;28:139–142.
12.
Casals J, Elizan T, Yahr MD: Postencephalitic parkinsonism – a review. J Neural Transm 1998;105:645–676.
13.
Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H: The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med 1995;181:2161–2169.
14.
Mori I, Diehl A, Chauhan A, Ljunggren H, Kristensson K: Selective targeting of habenular, thalamic midline and monoaminergic brainstem neurons by neurotropic influenza A virus in mice. J Neurovirol 1999;5:355–362.
15.
Kasai T, Togashi T, Morishima T: Encephalopathy associated with influenza epidemics. Lancet 2000;355:1558–1559.
16.
Okabe N, Yamashita K, Taniguchi K, Inouye S: Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season. Pediatr Int 2000;42:187–191.
17.
Togashi T, Matsuzono Y, Narita M: Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int 2000;42:192–196.
18.
Sulkava R, Rissanen A, Pyhala R: Post-influenzal encephalitis during the influenza A outbreak in 1979/1980. J Neurol Neurosurg Psychiatry 1981;44:161–163.
19.
Sivertsen B, Christensen PB: Acute encephalitis. Acta Neurol Scand 1996;93:156–159.
20.
Studahl M, Bergström T, Hagberg L: Acute viral encephalitis in adults – a prospective study. Scand J Infect Dis 1998;30:215–220.
21.
Yoshikawa H, Yamazaki S, Watanabe T, Abe T: Study of influenza-associated encephalitis/encephalopathy in children during the 1997 to 2001 influenza seasons. J Child Neurol 2001;16:885–890.
22.
Wong V, Yeung CY: Acute viral encephalitis in children. Aust Paediatr J 1987;23:339–342.
23.
Prabhakar P, Bailey V: Influenza virus infections in Jamaica between 1977 and 1985. West Indian Med J 1987;36:131–139.
24.
Kumar R, Mathur A, Kumar A, Sethi GD, Sharma S, Chaturvedi UC: Virological investigations of acute encephalopathy in India. Arch Dis Child 1990;65:1227–1230.
25.
Kolski H, Ford-Jones EL, Richardson S, Petric M, Nelson S, Jamieson F, Blaser S, Gold R, Otsubo H, Heurter H, MacGregor D: Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994–1995. Clin Infect Dis 1998;26:398–409.
26.
Koskiniemi M, Rantalaiho T, Piiparinen H, von Bonsdorff CH, Farkkila M, Jarvinen A, Kinnunen E, Koskiniemi S, Mannonen L, Muttilainen M, Linnavuori K, Porras J, Puolakkainen M, Raiha K, Salonen EM, Ukkonen P, Vaheri A, Valtonen V: Infections of the central nervous system of suspected viral origin: a collaborative study from Finland. J Neurovirol 2001;7:400–408.
27.
Swedish National Board of Health and Welfare homepage, in Swedish, http://www.socialstyrelsen.se/Statistik/statistik_amne/dodsorsaker/index.htm.
28.
Davis LE, Kornfeld M, Daniels RS, Skehel JJ: Experimental influenza causes a non-permissive viral infection of brain, liver and muscle. J Neurovirol 2000;6:529–553.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.